// App-Quantinova.ai

[AB0275] : ONE-YEAR TREATMENT PATTERNS AND HEALTHCARE RESOURCE USE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS NEWLY INITIATING TREATMENT WITH BIOLOGIC DMARDS

Researchers

Presenter

  • J. Harnett

Principal Investigators

  • R. Gerber

  • D. Gruben

  • D. Wiederkehr

  • E.Y. Mahgoub

  • G. Wallenstein

  • A. Koenig

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Renal disease

  • Hypertension

  • Inflammatory Arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Certolizumab pegol

  • Methotrexate

  • Tocilizumab

  • HWA-486

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • golimumab

  • Rituximab

  • Anakinra

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved